Comparative Pharmacology
Head-to-head clinical analysis: ADVIL ALLERGY SINUS versus NAPHCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL ALLERGY SINUS versus NAPHCON A.
ADVIL ALLERGY SINUS vs NAPHCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
Naphcon-A combines naphazoline, an alpha-adrenergic receptor agonist, and pheniramine, a histamine H1-receptor antagonist. Naphazoline constricts conjunctival blood vessels via alpha-adrenergic stimulation, reducing redness and edema. Pheniramine blocks histamine effects, alleviating itching and allergic reactions.
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
1-2 drops instilled into the conjunctival sac every 3-4 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Naphazoline: ~2-3 hours; antazoline: ~3-4 hours. Clinical context: ocular administration, systemic absorption minimal.
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
Primarily renal excretion of unchanged drug and metabolites; naphazoline <10% unchanged, antazoline ~30% unchanged. Biliary/fecal elimination negligible.
Category C
Category C
NSAID/Decongestant/Antihistamine Combination
Ophthalmic Antihistamine/Decongestant